Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
| Distributed by / for | TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454 |
| NDC | 0093-7961-56 |
| Full product label | Amlodipine and Valsartan Tablets 10 mg/160 mg, (a) 30-count bottles (NDC 0093-7961-56) & 90-count bottles (NDC 0093-7691-98), RX Only, Manufactured In Israel By: TEVA PHARMACEUTICAL IND. LTD. Jerusalem, 9777402, Israel, Manufactured For: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454. |
| Recalling firm | Teva Pharmaceuticals USA |
| Distribution | USA Nationwide including Puerto Rico. |
| Quantity | 39,617 bottles |
| Recall initiated | 2018-11-27 |
| Report date | 2018-12-19 |
| Recall completed | — |
| Recall number | D-0304-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | North Wales PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗